Ondexxya (andexanet alfa): Avoid use of andexanet prior to heparinization
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
Medicine name |
Ondexxya
|
Active substance |
andexanet alfa
|
Therapeutic area (MeSH) |
Drug-Related Side Effects and Adverse Reactions
|
Procedure number |
EMEA/H/C/004108/II/0011
|
Regulatory outcome |
Variation
|
DHPC type |
Adverse event
|
Human ATC code |
V03AB
|
Dissemination date |
04/11/2020
|